Medical Care Technologies Pivots to Diversified AI Vision Portfolio

Medical Care Technologies Inc. (OTCID:MDCE) is transitioning from a specialized preventive healthcare focus to a diversified technology model. The company is now leveraging AI vision capabilities across several high-value verticals, including health, wellness, nutrition, and enterprise imaging.

As part of this strategic shift, the company has introduced two distinct AI-driven tools. In the healthcare sector, the MDCE Melanoma Scan Beta serves as an AI-assisted imaging and body-map monitoring application. Currently in its beta phase, the tool is seeking volunteer cohorts to provide real-world image datasets. According to CEO Marshall Perkins, moving toward human-submitted images is a "major step up" from relying exclusively on established public datasets such as ISIC and HAM10000, as it allows the platform to be evaluated against real-world input.

Simultaneously, the company has launched StrainScan Pro, an AI vision platform tailored for the agriculture and foodservice industries. Designed for deployment on portable devices like the iPad Air, the software performs visual quality analysis and consistency checks. Perkins noted that these sectors represent enormous markets with a clear need for practical AI tools that help operators maintain visual standards from the field to the kitchen and identify problems earlier in the production chain.

Strategic Market Pivot

This diversification represents an attempt by the Mesa, Arizona-based company to penetrate multi-trillion-dollar global markets. By offering portable quality-control tools for enterprise use, MDCE is moving away from a narrow medical niche toward a broader "diversified technology company" identity. This approach allows the firm to apply a single core competency—AI vision—across vastly different industrial applications.

While the company develops these new AI tools, it continues to generate revenue through its operating subsidiaries. This financial foundation includes businesses in the collectibles and memorabilia industry, specifically through entities such as Real Game Used and Infinite Auctions.

Industry Implications

For the healthcare market, the move toward real-world data validation for the Melanoma Scan Beta is a critical technical milestone. Validating AI tools with diverse, human-submitted data is typically a prerequisite for pursuing future regulatory clearances and ensuring clinical reliability across different skin types and lighting conditions.

In the enterprise sector, the deployment of AI on consumer-grade hardware like the iPad Air suggests a push toward democratizing high-end quality control. If successful, such tools could reduce waste and improve consistency in food supply chains by replacing subjective human inspection with standardized AI analysis.

Future Outlook

Investors and industry observers will likely monitor the results of the Melanoma Scan Beta's volunteer testing to see if the tool maintains accuracy outside of controlled public datasets. Additionally, the company's ability to scale StrainScan Pro within the agriculture sector will determine if its pivot to enterprise imaging can provide a sustainable growth engine alongside its existing memorabilia revenue streams.